Orogen Royalties Announces Project, Partner and Royalty Update
Orogen Royalties Begins Trading on OTCQX Best Market
Organon wins US approval to widen use of arthritis biosimilar drug
Orogen Reports Strong Q1 2026 Results with 144% Growth in Net Income
Orogen Royalties Appoints Mr. Chad Wells to the Board of Directors
Orogen Royalties Reports Record Revenue and Strong Earnings Growth in 2025